Invivyd (IVVD) Receivables (2023 - 2026)
Invivyd's (IVVD) quarterly Receivables came in at $11.7 million in Q2 2026, up 32.63% on a YoY basis from $8.8 million in Q2 2025, and down 19.95% quarter-over-quarter from $14.6 million in Q4 2025.
Analysis
Invivyd (IVVD) Receivables (2023 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Receivables for 4 consecutive years, with $11.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Receivables rose 32.63% year-over-year to $11.7 million; the trailing twelve-month figure through Jun 2026 stood at $11.7 million (up 32.63% YoY), and the FY2025 full-year result was $14.6 million, up 30.67% from the prior year.
- Receivables eased to $11.7 million in Q2 2026 per IVVD's latest filing, from $14.6 million in the prior quarter.
- Across five years, Receivables topped out at $14.6 million in Q4 2025 and bottomed at $933000.0 in Q4 2023.
- Historically, Receivables has averaged $8.7 million across 4 years, with a median of $8.8 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Receivables surged 1097.11% in 2024, then climbed 17.02% in 2025.
- Over 4 years, Receivables stood at $933000.0 in 2023, then soared by 1097.11% to $11.2 million in 2024, then soared by 30.67% to $14.6 million in 2025, then retreated by 19.95% to $11.7 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $11.7 million, $14.6 million, and $10.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 11.68 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.68 Mn |
| Dec 31, 2025 | 14.60 Mn |
| Sep 30, 2025 | 10.13 Mn |
| Jun 30, 2025 | 8.81 Mn |
| Mar 31, 2025 | 8.75 Mn |
| Dec 31, 2024 | 11.17 Mn |
| Sep 30, 2024 | 8.66 Mn |
| Jun 30, 2024 | 3.54 Mn |
| Dec 31, 2023 | 933,000.00 |